JCRファーマ株式会社 FY2025 第三四半期決算説明資料

This document is the FY2025 Third Quarter Results Briefing material for JCR Pharmaceuticals Co., Ltd. It reports a 17.3% increase in net sales compared to the previous year, primarily driven by upfront and milestone payments from licensing agreements. Selling, general and administrative expenses rose due to increased co-promotion fees in line with sales growth. Research and development expenses also increased following upfront payments for license rights. Non-operating income significantly rose due to foreign exchange gains, while extraordinary income reflected subsidies for the Kobe Science Park Center. Overall, operating profit improved from the previous year, and profit attributable to owners of the parent increased substantially.